Geoffrey Lynn | Chief Executive Officer and Co-Founder
Avidea Technologies

Geoffrey Lynn, Chief Executive Officer and Co-Founder, Avidea Technologies

Dr. Geoffrey Lynn is CEO and Co-founder of Avidea Technologies (Baltimore, MD). In this capacity, Dr. Lynn is leveraging his background in synthetic chemistry and cellular immunology to lead Avidea’s efforts to develop immunotherapies for cancer treatment that are enabled by innovations around two platform drug delivery technologies: self-assembling nanoparticles based on amphiphilic polymers (“SNAP”) and star polymers. Prior to joining Avidea, Dr. Lynn worked on the development of synthetic vaccines for inducing T cell immunity as a postdoctoral trainee with Dr. Robert Seder at the Vaccine Research Center (National Institutes of Health) and received a PhD in biomedical engineering from Oxford University for his work with Prof. Leonard Seymour on polymer drug delivery systems for improving the PK and PD of immunostimulants.  

Appearances:



Festival of Biologics Day 2 @ 14:20

Leveraging antibody & T cell immunity with IV administrable glycopeptide cancer vaccines

last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers